Adeno Associated Virus 9-Based Gene Therapy Delivers a Functional Monocarboxylate Transporter 8, Improving Thyroid Hormone Availability to the Brain of Mct8-Deficient Mice

Hideyuki Iwayama, Xiao Hui Liao, Lyndsey Braun, Soledad Bárez-López, Brian Kaspar, Roy E Weiss, Alexandra M. Dumitrescu, Ana Guadaño-Ferraz, Samuel Refetoff

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Background: MCT8 gene mutations produce thyroid hormone (TH) deficiency in the brain, causing severe neuropsychomotor abnormalities not correctable by treatment with TH. This proof-of-concept study examined whether transfer of human MCT8 (hMCT8) cDNA using adeno-associated virus 9 (AAV9) could correct the brain defects of Mct8 knockout mice (Mct8KO). Methods: AAV9 vectors delivering long and/or short hMCT8 protein isoforms or an empty vector were injected intravenously (IV) and/or intracerebroventricularly (ICV) into postnatal day 1 Mct8KO and wild type (Wt) mice. Triiodothyronine (T3) was given daily for four days before postnatal day 28, at which time brains were collected after perfusion to assess increase in T3 content and effect on the T3-responsive transcription factor, Hairless. Results: Increased pup mortality was observed after IV injection of the AAV9-long hMCT8 isoform, but not after injection of AAV9-short hMCT8 isoform. Compared to IV, ICV delivery produced more hMCT8 mRNA and protein relative to the viral dose, which was present in various brain regions and localized to the cell membranes. Despite production of abundant hMCT8 mRNA and protein with ICV delivery, only IV delivered AAV9-hMCT8 targeted the choroid plexus and significantly increased brain T3 content and expression of Hairless. Conclusions: These results indicate that MCT8 delivery to brain barriers by IV but not ICV injection is crucial for its proper function. MCT8 has no constitutive activity but acts through an increase in T3 entering the brain tissue. Increasing MCT8 expression in brain cell membranes, including neurons, is insufficient to produce an effect without an increase in brain T3 content. The correct hMCT8 isoform along with an optimized delivery method are critical for an effective gene therapy to provide functional MCT8 in the brain of patients with MCT8 mutations.

Original languageEnglish (US)
Pages (from-to)1311-1319
Number of pages9
JournalThyroid
Volume26
Issue number9
DOIs
StatePublished - Sep 1 2016

Fingerprint

Dependovirus
Thyroid Hormones
Genetic Therapy
Brain
Protein Isoforms
Knockout Mice
Injections
Cell Membrane
Messenger RNA
Mutation
Choroid Plexus
Triiodothyronine
Transcription Factors
Complementary DNA
Perfusion
Neurons

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Adeno Associated Virus 9-Based Gene Therapy Delivers a Functional Monocarboxylate Transporter 8, Improving Thyroid Hormone Availability to the Brain of Mct8-Deficient Mice. / Iwayama, Hideyuki; Liao, Xiao Hui; Braun, Lyndsey; Bárez-López, Soledad; Kaspar, Brian; Weiss, Roy E; Dumitrescu, Alexandra M.; Guadaño-Ferraz, Ana; Refetoff, Samuel.

In: Thyroid, Vol. 26, No. 9, 01.09.2016, p. 1311-1319.

Research output: Contribution to journalArticle

Iwayama, H, Liao, XH, Braun, L, Bárez-López, S, Kaspar, B, Weiss, RE, Dumitrescu, AM, Guadaño-Ferraz, A & Refetoff, S 2016, 'Adeno Associated Virus 9-Based Gene Therapy Delivers a Functional Monocarboxylate Transporter 8, Improving Thyroid Hormone Availability to the Brain of Mct8-Deficient Mice', Thyroid, vol. 26, no. 9, pp. 1311-1319. https://doi.org/10.1089/thy.2016.0060
Iwayama, Hideyuki ; Liao, Xiao Hui ; Braun, Lyndsey ; Bárez-López, Soledad ; Kaspar, Brian ; Weiss, Roy E ; Dumitrescu, Alexandra M. ; Guadaño-Ferraz, Ana ; Refetoff, Samuel. / Adeno Associated Virus 9-Based Gene Therapy Delivers a Functional Monocarboxylate Transporter 8, Improving Thyroid Hormone Availability to the Brain of Mct8-Deficient Mice. In: Thyroid. 2016 ; Vol. 26, No. 9. pp. 1311-1319.
@article{31aba4c1a5fd4ef48596af56ccb2ceb0,
title = "Adeno Associated Virus 9-Based Gene Therapy Delivers a Functional Monocarboxylate Transporter 8, Improving Thyroid Hormone Availability to the Brain of Mct8-Deficient Mice",
abstract = "Background: MCT8 gene mutations produce thyroid hormone (TH) deficiency in the brain, causing severe neuropsychomotor abnormalities not correctable by treatment with TH. This proof-of-concept study examined whether transfer of human MCT8 (hMCT8) cDNA using adeno-associated virus 9 (AAV9) could correct the brain defects of Mct8 knockout mice (Mct8KO). Methods: AAV9 vectors delivering long and/or short hMCT8 protein isoforms or an empty vector were injected intravenously (IV) and/or intracerebroventricularly (ICV) into postnatal day 1 Mct8KO and wild type (Wt) mice. Triiodothyronine (T3) was given daily for four days before postnatal day 28, at which time brains were collected after perfusion to assess increase in T3 content and effect on the T3-responsive transcription factor, Hairless. Results: Increased pup mortality was observed after IV injection of the AAV9-long hMCT8 isoform, but not after injection of AAV9-short hMCT8 isoform. Compared to IV, ICV delivery produced more hMCT8 mRNA and protein relative to the viral dose, which was present in various brain regions and localized to the cell membranes. Despite production of abundant hMCT8 mRNA and protein with ICV delivery, only IV delivered AAV9-hMCT8 targeted the choroid plexus and significantly increased brain T3 content and expression of Hairless. Conclusions: These results indicate that MCT8 delivery to brain barriers by IV but not ICV injection is crucial for its proper function. MCT8 has no constitutive activity but acts through an increase in T3 entering the brain tissue. Increasing MCT8 expression in brain cell membranes, including neurons, is insufficient to produce an effect without an increase in brain T3 content. The correct hMCT8 isoform along with an optimized delivery method are critical for an effective gene therapy to provide functional MCT8 in the brain of patients with MCT8 mutations.",
author = "Hideyuki Iwayama and Liao, {Xiao Hui} and Lyndsey Braun and Soledad B{\'a}rez-L{\'o}pez and Brian Kaspar and Weiss, {Roy E} and Dumitrescu, {Alexandra M.} and Ana Guada{\~n}o-Ferraz and Samuel Refetoff",
year = "2016",
month = "9",
day = "1",
doi = "10.1089/thy.2016.0060",
language = "English (US)",
volume = "26",
pages = "1311--1319",
journal = "Thyroid",
issn = "1050-7256",
publisher = "Mary Ann Liebert Inc.",
number = "9",

}

TY - JOUR

T1 - Adeno Associated Virus 9-Based Gene Therapy Delivers a Functional Monocarboxylate Transporter 8, Improving Thyroid Hormone Availability to the Brain of Mct8-Deficient Mice

AU - Iwayama, Hideyuki

AU - Liao, Xiao Hui

AU - Braun, Lyndsey

AU - Bárez-López, Soledad

AU - Kaspar, Brian

AU - Weiss, Roy E

AU - Dumitrescu, Alexandra M.

AU - Guadaño-Ferraz, Ana

AU - Refetoff, Samuel

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Background: MCT8 gene mutations produce thyroid hormone (TH) deficiency in the brain, causing severe neuropsychomotor abnormalities not correctable by treatment with TH. This proof-of-concept study examined whether transfer of human MCT8 (hMCT8) cDNA using adeno-associated virus 9 (AAV9) could correct the brain defects of Mct8 knockout mice (Mct8KO). Methods: AAV9 vectors delivering long and/or short hMCT8 protein isoforms or an empty vector were injected intravenously (IV) and/or intracerebroventricularly (ICV) into postnatal day 1 Mct8KO and wild type (Wt) mice. Triiodothyronine (T3) was given daily for four days before postnatal day 28, at which time brains were collected after perfusion to assess increase in T3 content and effect on the T3-responsive transcription factor, Hairless. Results: Increased pup mortality was observed after IV injection of the AAV9-long hMCT8 isoform, but not after injection of AAV9-short hMCT8 isoform. Compared to IV, ICV delivery produced more hMCT8 mRNA and protein relative to the viral dose, which was present in various brain regions and localized to the cell membranes. Despite production of abundant hMCT8 mRNA and protein with ICV delivery, only IV delivered AAV9-hMCT8 targeted the choroid plexus and significantly increased brain T3 content and expression of Hairless. Conclusions: These results indicate that MCT8 delivery to brain barriers by IV but not ICV injection is crucial for its proper function. MCT8 has no constitutive activity but acts through an increase in T3 entering the brain tissue. Increasing MCT8 expression in brain cell membranes, including neurons, is insufficient to produce an effect without an increase in brain T3 content. The correct hMCT8 isoform along with an optimized delivery method are critical for an effective gene therapy to provide functional MCT8 in the brain of patients with MCT8 mutations.

AB - Background: MCT8 gene mutations produce thyroid hormone (TH) deficiency in the brain, causing severe neuropsychomotor abnormalities not correctable by treatment with TH. This proof-of-concept study examined whether transfer of human MCT8 (hMCT8) cDNA using adeno-associated virus 9 (AAV9) could correct the brain defects of Mct8 knockout mice (Mct8KO). Methods: AAV9 vectors delivering long and/or short hMCT8 protein isoforms or an empty vector were injected intravenously (IV) and/or intracerebroventricularly (ICV) into postnatal day 1 Mct8KO and wild type (Wt) mice. Triiodothyronine (T3) was given daily for four days before postnatal day 28, at which time brains were collected after perfusion to assess increase in T3 content and effect on the T3-responsive transcription factor, Hairless. Results: Increased pup mortality was observed after IV injection of the AAV9-long hMCT8 isoform, but not after injection of AAV9-short hMCT8 isoform. Compared to IV, ICV delivery produced more hMCT8 mRNA and protein relative to the viral dose, which was present in various brain regions and localized to the cell membranes. Despite production of abundant hMCT8 mRNA and protein with ICV delivery, only IV delivered AAV9-hMCT8 targeted the choroid plexus and significantly increased brain T3 content and expression of Hairless. Conclusions: These results indicate that MCT8 delivery to brain barriers by IV but not ICV injection is crucial for its proper function. MCT8 has no constitutive activity but acts through an increase in T3 entering the brain tissue. Increasing MCT8 expression in brain cell membranes, including neurons, is insufficient to produce an effect without an increase in brain T3 content. The correct hMCT8 isoform along with an optimized delivery method are critical for an effective gene therapy to provide functional MCT8 in the brain of patients with MCT8 mutations.

UR - http://www.scopus.com/inward/record.url?scp=84986213021&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84986213021&partnerID=8YFLogxK

U2 - 10.1089/thy.2016.0060

DO - 10.1089/thy.2016.0060

M3 - Article

VL - 26

SP - 1311

EP - 1319

JO - Thyroid

JF - Thyroid

SN - 1050-7256

IS - 9

ER -